For health authorities
For payers, hospitals and health authorities, our technology drives economies of scale by minimizing complications that are costly and, consequently, enable more patients to transition to homecare.
For health professionals
For nurses and health professionals, we offer benefits from user-friendly tech that simplifies workflows and minimizes risks (infections & mechanical dysfunctions), enhancing confidence during procedures.
For patients, our technology ensures improved quality of care through a safe, pain-free, reliable, and plug-and-play device, enabling seamless use and supporting home-based treatments.
For patients
Our mission: Create safer vascular access.
We want to facilitate the transition from hospital to home. It will be easier for patients to maintain professional activities and it will have a positive effect on morale and fight against social isolation.
Delivering a unique value proposition
Vision
At SÆPTUM, we are driven to provide safer and more efficient care. We develop tech of revolutionary impact: improving patients' quality of life by reducing the risk of infection and facilitating independent care; supporting healthcare professionals by providing them with high-performance, reliable tools; and reducing public health costs by limiting the medical complications associated with vascular access infections.
Our vision encompasses reducing the costs associated with infections, in particular by decreasing hospital admissions, lowering drug consumption, reducing the risk of mortality, and improving clinical outcomes.
For patients
For health authorities
For health professionals
At SÆPTUM, we combine two very important values: qualitative products and users satisfaction. This is why our motto says “Designed for care”: care of the patient, care of the health professionals, care of the health system. Our team, a combination of medical R&D and medtech experts, strives towards continuous efficiency and innovation.
From dialysis to infusion therapies more broadly, from vascular access to ground-breaking implants, SÆPTUM values continuous innovation to design medical devices that make a difference.
Continuous improvements is a central part of our values, so that our tech becomes the new gold standard for its durability, ease of use, and health benefits.
Values
Mission
At SÆPTUM, our mission is to develop innovative tech to meet the challenges associated with vascular access and infusion therapies. We focus on reducing infections, easing the patient pathway and advancing homecare solutions.
As a spin-off company, SÆPTUM combines our strengths to innovate and transform care delivery through deeptech excellence.
By offering ergonomic medical devices, we encourage patients to manage their own care, and we lift technical burdens on health practitioners. We aim to revolutionise the way we treat complex patients, empowering them with more accessible solutions.
We listen
We innovate
We care
Less infections
Easier handling
Safer outcomes
About us
Multidisciplinarity that fosters excellence.
We are a team with a deep expertise in medical devices and infection prevention, including input from key academic experts in our scientific board. We united around a shared vision: revolutionise care for patients requiring vascular access.
Creative
Passionate
Human
Agile
As the aging population grows, these challenges will intensify, demanding innovative solutions to improve safety, care, and patient outcomes. Looking ahead to 2035, an estimated 50 million patients may require vascular access, encompassing not only haemodialysis but also broader clinical needs such as chemotherapy, parenteral nutrition, and other therapies.
This expanding patient base underlines a critical and urgent demand for safer, more efficient, and patient-centric vascular access technologies.
Infusion therapies today
Infusion therapy delivers medication through a needle or a catheter, often intravenously.
For life-saving infusion therapies like chemotherapy, intensive care or haemodialysis, accessing the bloodstream safely and effectively is vital yet current methods present significant challenges.
Advantages
-
Blood flow adaptation
-
Set custom parameters
-
Custom session duration
-
Extra-corporeal circulation monitoring
These challenges demand innovative answers to improve safety, care, and patient outcomes.
They make home treatments more hazardous, as continuous monitoring of vascular access is essential to predict and prevent complications.
Life threatening challenges
-
Infections
-
Phlebitis
-
Thrombosis
-
Air embolism
-
Collapsed veins
-
Needle dislodgement, causing haemorrhage or death
At SÆPTUM, we aim to answer these challenges with new state-of-the-art, gold standard medical tech that is easy to use and easy to live with, cheaper and safer, designed for care.
About infusion therapies
“Bloodstream infections are an important cause of hospitalizations, morbidity, and mortality in patients receiving hemodialysis. [However], hemodialysis catheter-associated bloodstream infections continue to occur at unacceptable rates […].” (Fisher et al., 2020)
“Home hemodialysis provides an opportunity to improve patient outcomes, lower overall cost of care, address nurse resource limitations, and provide patients with greater autonomy with the goal to improve the patient experience.” (Aragon et al., 2024)
Testimonies
SÆPTUM innovates by introducing groundbreaking port technology that facilitates extracorporeal treatments, including dialysis, with unparalleled safety and usability. As a care enabler, Saeptum will transform the landscape of patient-centered innovation, seamlessly integrating advanced technology to optimize clinician workflows and improve patient outcomes.
Pr. Bernard Canaud - Nephrologist
Testimonies
SÆPTUM is a disruptive company revolutionizing the MedTech sector with innovative, cutting-edge solutions. Thanks to a bold approach and its state-of-the-art technology, SÆPTUM redefines the rules of healthcare solutions by anticipating tomorrow's needs. Its unique vision makes it a key player, ready to transform today's healthcare challenges into tomorrow's opportunities.
Dr. Hafedh FESSI - Nephrologist & renal therapies expert
With our expertise in the health sector and vascular access, we give patients the possibility to be in full possession of their own treatment, to live the life they want, safely.
About our tech
Answering vascular access challenges
Against infection risks.
Improving quality of life.
Cutting care costs.
With superior patency and higher blood flow rates, our tech delivers exceptional reliability and efficiency for patients and caregivers.
A key player in preventive and predictive medecine.
We aim to incorporate sensors that make it easier to monitor patients and anticipate potential problems. With simple, ergonomic tech, we also aim to reduce the training time required for carers.
A key goal at SÆPTUM: facilitate a better organisation of care.
From a standardised to a customised approach to treatment: the “right access, in the right patient, at the right time, for the right reasons.” (Lok et al., 2021)
Our maintenance-free device offers substantial savings while minimising adverse events such as infections, thrombosis, and stenosis.
SÆPTUM has acquired the vascular access technology HemoPlug™.
Its developments were largely supported by local authorities,
the French government and the European union.
Starting with haemodialysis, our tech opens a field of possibilities for other medical uses, such as our vascular access implant and other developments related to infusion therapies.
A patented, innovative, clinically trialled smart valve system: HemoPlug™.
We have registered developped the HemoPlug™ technology, patented in the US and Europe, asserting the tech’s innovative
potential as protected and validated. For our implant project, pre-clinical trials confirmed both the feasibility of the surgery and the
ability to perform extracorporeal circulation.
Our partners: stock exchange-listed, strategic industry players.
Our knowledge about vascular access and haemodialysis needs has been strengthened by thorough market research involving
focus groups with focus groups with main stakeholders in Europe and in the US.